MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561739 | Name: Dimethyl Fumarate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dimethyl Fumarate is an immunomodulator that acts by inhibiting pathogenic immune responses with Th17/Th1T cells and IL-23/IL-12 producing dendritic cells (DCs).

Chemical Structure

Dimethyl Fumarate
CAS#624-49-7

Theoretical Analysis

MedKoo Cat#: 561739

Name: Dimethyl Fumarate

CAS#: 624-49-7

Chemical Formula: C6H8O4

Exact Mass: 144.0423

Molecular Weight: 144.13

Elemental Analysis: C, 50.00; H, 5.60; O, 44.40

Price and Availability

Size Price Availability Quantity
10g USD 250.00 2 Weeks
25g USD 450.00 2 Weeks
50g USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Dimethyl Fumarate; Dimethylfumarate; DMF; Tecfidera; (E)-Dimethyl fumarate; Dimethylfumarate; NSC 25942; NSC25942; NSC-25942; NSC 167432; NSC167432; NSC-167432
IUPAC/Chemical Name
But-2-enedioic acid dimethyl ester
InChi Key
LDCRTTXIJACKKU-ONEGZZNKSA-N
InChi Code
InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+
SMILES Code
O=C(OC)/C=C/C(OC)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C20M06C25
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression.
In vitro activity:
As shown in Figure 1A, DMF (dimethyl fumarate) dose-dependently reduced the viability of SGC-7901, HT29, HCT116 and CT26 cancer cells in the range 20–200 μM. Reference: Br J Pharmacol. 2015 Aug;172(15):3929-43. https://pubmed.ncbi.nlm.nih.gov/25953698/
In vivo activity:
In vivo, DMF (dimethyl fumarate) oral administration was shown to upregulate mRNA and protein levels of Nrf2 and Nrf2-regulated cytoprotective genes, attenuate 6-OHDA induced striatal oxidative stress and inflammation in C57BL/6 mice. Moreover, DMF ameliorated dopaminergic neurotoxicity in 6-OHDA-induced PD animal models as evidenced by amelioration of locomotor dysfunction, loss in striatal dopamine, and reductions in dopaminergic neurons in the substantia nigra and striatum. Taken together, these data strongly suggest that DMF may be beneficial for the treatment of neurodegenerative diseases like PD. Reference: Neuroscience. 2015 Feb 12;286:131-40. https://pubmed.ncbi.nlm.nih.gov/25449120/
Solvent mg/mL mM comments
Solubility
DMF 12.0 83.26
DMF:PBS (pH 7.2) (1:1) 0.5 3.47
DMSO 32.2 223.18
Ethanol 6.0 41.63
Water 8.3 57.80
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 144.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Xie X, Zhao Y, Ma CY, Xu XM, Zhang YQ, Wang CG, Jin J, Shen X, Gao JL, Li N, Sun ZJ, Dong DL. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway. Br J Pharmacol. 2015 Aug;172(15):3929-43. doi: 10.1111/bph.13184. Epub 2015 Jun 12. PMID: 25953698; PMCID: PMC4523346. 2. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012 Aug 10;287(33):28017-26. doi: 10.1074/jbc.M112.383380. Epub 2012 Jun 25. PMID: 22733812; PMCID: PMC3431702. 3. Jing X, Shi H, Zhang C, Ren M, Han M, Wei X, Zhang X, Lou H. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity. Neuroscience. 2015 Feb 12;286:131-40. doi: 10.1016/j.neuroscience.2014.11.047. Epub 2014 Nov 29. PMID: 25449120. 4. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012 Apr;341(1):274-84. doi: 10.1124/jpet.111.190132. Epub 2012 Jan 20. PMID: 22267202.
In vitro protocol:
1. Xie X, Zhao Y, Ma CY, Xu XM, Zhang YQ, Wang CG, Jin J, Shen X, Gao JL, Li N, Sun ZJ, Dong DL. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway. Br J Pharmacol. 2015 Aug;172(15):3929-43. doi: 10.1111/bph.13184. Epub 2015 Jun 12. PMID: 25953698; PMCID: PMC4523346. 2. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012 Aug 10;287(33):28017-26. doi: 10.1074/jbc.M112.383380. Epub 2012 Jun 25. PMID: 22733812; PMCID: PMC3431702.
In vivo protocol:
1. Jing X, Shi H, Zhang C, Ren M, Han M, Wei X, Zhang X, Lou H. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity. Neuroscience. 2015 Feb 12;286:131-40. doi: 10.1016/j.neuroscience.2014.11.047. Epub 2014 Nov 29. PMID: 25449120. 2. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012 Apr;341(1):274-84. doi: 10.1124/jpet.111.190132. Epub 2012 Jan 20. PMID: 22267202.
1: Satoh T, Lipton S. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res. 2017 Dec 14;6:2138. doi: 10.12688/f1000research.12111.1. eCollection 2017. Review. PubMed PMID: 29263788; PubMed Central PMCID: PMC5730864. 2: Jančić J, Nikolić B, Ivančević N, Henčić B, Samardžić J. Multiple Sclerosis Therapies in Pediatric Patients: Challenges and Opportunities. In: Zagon IS, McLaughlin PJ, editors. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]. Brisbane (AU): Codon Publications; 2017 Nov 27. Chapter 3. Available from http://www.ncbi.nlm.nih.gov/books/NBK470149/ PubMed PMID: 29261267. 3: Tanaka M, Shimizu Y. [Dimethyl Fumarate in Multiple Sclerosis]. Brain Nerve. 2017 Sep;69(9):1041-1046. doi: 10.11477/mf.1416200864. Review. Japanese. PubMed PMID: 28900067. 4: Liddell JR. Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration? Antioxidants (Basel). 2017 Aug 18;6(3). pii: E65. doi: 10.3390/antiox6030065. Review. PubMed PMID: 28820437; PubMed Central PMCID: PMC5618093. 5: Guarnera C, Bramanti P, Mazzon E. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2017 Jul 28;11:2193-2207. doi: 10.2147/DDDT.S137572. eCollection 2017. Review. PubMed PMID: 28814828; PubMed Central PMCID: PMC5546180. 6: Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J, Apostolopoulos V. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci. 2017 Jul 7;7(7). pii: E78. doi: 10.3390/brainsci7070078. Review. PubMed PMID: 28686222; PubMed Central PMCID: PMC5532591. 7: Institute for Quality and Efficiency in Health Care. Addendum to Commission A14-14 (Dimethyl Fumarate) [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2014 Sep 25. Available from http://www.ncbi.nlm.nih.gov/books/NBK385677/ PubMed PMID: 28609068. 8: Institute for Quality and Efficiency in Health Care. Dimethyl Fumarate -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2014 Jul 30. Available from http://www.ncbi.nlm.nih.gov/books/NBK385691/ PubMed PMID: 28609060. 9: Kasarełło K, Cudnoch-Jędrzejewska A, Członkowski A, Mirowska-Guzel D. Mechanism of action of three newly registered drugs for multiple sclerosis treatment. Pharmacol Rep. 2017 Aug;69(4):702-708. doi: 10.1016/j.pharep.2017.02.017. Epub 2017 Feb 22. Review. PubMed PMID: 28550802. 10: Staun-Ram E, Miller A. Effector and regulatory B cells in Multiple Sclerosis. Clin Immunol. 2017 Nov;184:11-25. doi: 10.1016/j.clim.2017.04.014. Epub 2017 Apr 28. Review. PubMed PMID: 28461106. 11: Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review. PubMed PMID: 28440858. 12: Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. Pharmacol Res. 2017 Jun;120:279-293. doi: 10.1016/j.phrs.2017.03.025. Epub 2017 Apr 8. Review. PubMed PMID: 28396093. 13: Schmidt E, Spindler V, Eming R, Amagai M, Antonicelli F, Baines JF, Belheouane M, Bernard P, Borradori L, Caproni M, Di Zenzo G, Grando S, Harman K, Jonkman MF, Koga H, Ludwig RJ, Kowalczyk AP, Müller EJ, Nishie W, Pas H, Payne AS, Sadik CD, Seppänen A, Setterfield J, Shimizu H, Sinha AA, Sprecher E, Sticherling M, Ujiie H, Zillikens D, Hertl M, Waschke J. Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. J Invest Dermatol. 2017 Jun;137(6):1199-1203. doi: 10.1016/j.jid.2017.01.028. Epub 2017 Apr 5. Review. PubMed PMID: 28390814. 14: Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. Br J Radiol. 2017 Jun;90(1074):20160721. doi: 10.1259/bjr.20160721. Epub 2017 Apr 26. Review. PubMed PMID: 28362522; PubMed Central PMCID: PMC5602172. 15: Huisman E, Papadimitropoulou K, Jarrett J, Bending M, Firth Z, Allen F, Adlard N. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open. 2017 Mar 10;7(3):e013430. doi: 10.1136/bmjopen-2016-013430. Review. PubMed PMID: 28283486; PubMed Central PMCID: PMC5353339. 16: Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017 Feb;12:59-63. doi: 10.1016/j.msard.2017.01.006. Epub 2017 Jan 6. Review. PubMed PMID: 28283109. 17: Misbah SA. Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency. Clin Exp Immunol. 2017 Jun;188(3):342-352. doi: 10.1111/cei.12948. Epub 2017 Mar 27. Review. PubMed PMID: 28245526; PubMed Central PMCID: PMC5422720. 18: Levite M. Glutamate, T cells and multiple sclerosis. J Neural Transm (Vienna). 2017 Jul;124(7):775-798. doi: 10.1007/s00702-016-1661-z. Epub 2017 Feb 24. Review. PubMed PMID: 28236206. 19: Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine. 2017 Feb;16:41-50. doi: 10.1016/j.ebiom.2017.01.042. Epub 2017 Jan 31. Review. PubMed PMID: 28161400; PubMed Central PMCID: PMC5474520. 20: Deleu D, Mesraoua B, El Khider H, Canibano B, Melikyan G, Al Hail H, Mhjob N, Bhagat A, Ibrahim F, Hanssens Y. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. Curr Med Res Opin. 2017 Mar;33(3):439-458. doi: 10.1080/03007995.2016.1261818. Epub 2016 Dec 31. Review. PubMed PMID: 27892723.